Suven Life Sciences (SUVEN) — concall transcript

📢 Key Event
Suven Life Sciences' SUVN-502 failed primary endpoint despite strong safety profile; SUVN-G3031 enrollment at 20% with FY21 March potential completion.

🔄 What Changed
SUVN-502 project disappointment; SUVN-G3031 Phase II progress; CAPEX spend update; book value figures; cash balances; strategic investor mention; listing status update.

🔮 What's Next
SUVN-G3031 may complete by FY21 March; monetization possible in Q3-Q4 2021; US IPO target for Suven Neurosciences in 2.5 years; 15%-22% FY20 revenue growth; CAPEX of ₹320 crores through FY21; listing timeline pending regulatory approval.

💡 Investor Takeaway
Suven Life Sciences faces pipeline uncertainty but has cash runway and strategic options; Suven Pharmaceuticals shows steady growth with demerger progress.

Suven Life Sciences reported disappointment with SUVN-502 failing its primary endpoint despite strong safety data, while SUVN-G3031 narcolepsy trial enrollment reached ~20% and may conclude in FY21 March. SUVN-D4010 indications are being finalized for Phase II within two months. Funding relies on Suven CRAMS cash reserves (~₹180 crores) and potential strategic partnerships or future US IPO for Suven Neurosciences. Suven Pharmaceuticals, now demerged, projects 15%-22% FY20 revenue growth with 3-part business expansion into APIs and formulations. CAPEX of ₹320 crores planned through FY21, with ₹160 crores already spent. Book value stands at ₹390 crores for Suven Life Sciences and ₹806 crores for Suven Pharmaceuticals. Gross margins remain volatile due to mixed product mix. Debt is minimal ([amount context mismatch]-35 crores working capital), with cash balances of ₹150 crores (Suven Life Sciences) and ₹213 crores (Suven Pharma). Strategic investor interest for CRAMS demerger is noted but no formal outreach yet. Listing timeline remains pending SEBI/BSE approval.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SUVEN ✨ Ask AI About This

About Suven Life Sciences Ltd (SUVEN)

Healthcare · Healthcare · Listed on BSE

Market Cap: ₹9,509.65 Cr ROE: -80.9% ROCE: -80.7%

View full SUVEN stock details →

📡 Get AI alerts when SUVEN files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SUVEN — Free

💡 Ask AI about this filing

"What is the exact timeline for SUVN-G3031 Phase II completion?" "When will Suven Pharmaceuticals receive SEBI listing approval?" "What is the expected monetization milestone for SUVN-D4010?"

Ask AI Free →

📊 More SUVEN filings

See all SUVEN filings →

🔥 Also filed on 31 December 2019

VIRINCHI Virinchi Ltd concall transcript RUCHIRA Ruchira Papers Ltd concall transcript

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SUVEN files new disclosures

Track SUVEN filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SUVEN — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd